EUVIMEDEUVIMED entdecken
Crossref

Anticancer Effects of Nortriptyline Hydrochloride in Osteosarcoma Cells Including Doxorubicin-resistant Cells

Yuki Uemichi, Miyuki Mabuchi, Shuji Nagano, Shuhei Nakao, Tadashi Shimizu

Anticancer Research · 2026-07 · 46 (7) · 3687-3698

DOI: 10.21873/anticanres.18233 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, online erschienen am 29.06.2026. Verfasst von Yuki Uemichi und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Hyogo Medical University, Kobe, Japan. Hauptthemen laut MEDLINE: Nortriptyline, Osteosarcoma, Doxorubicin, Drug Resistance, Neoplasm.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aim: Osteosarcoma (OS), the most common primary malignant bone tumor, is associated with a high risk of recurrence and metastasis, leading to poor prognosis. This study explored the potential use of drug repositioning by investigating nortriptyline hydrochloride (NTP) in osteosarcoma treatment. NTP, a classic tricyclic antidepressant used to treat psychiatric disorders, has been shown to have antitumor activity against several cancer types. Materials and Methods: We investigated the inhibitory effects of NTP on OS cell proliferation and migration. The anticancer activity of NTP was evaluated in terms of cell viability, chemical rescue by cell death inhibitors, lactate dehydrogenase (LDH) release, cytoskeletal staining, and cell cycle analysis. NTP inhibited the proliferation of OS cells and induced G0/G1 phase cell cycle arrest in a dose-dependent manner.

Results

The IC50 values of NTP were 24.2 μM and 15.8 μM for U2OS and MG-63 cell proliferation, respectively. Chemical rescue using cell death inhibitors and LDH release assays showed that the anticancer effects of NTP was mainly attributed to the inhibition of cell proliferation. Additionally, NTP inhibited cell migration, disrupted actin filament formation, and altered intracellular distribution. Furthermore, NTP retained growth inhibitory activity in doxorubicin-resistant OS cells.

Conclusion

NTP may serve as a novel therapeutic agent for preventing OS growth and metastasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NortriptylineOsteosarcomaDoxorubicinDrug Resistance, NeoplasmBone NeoplasmsAntineoplastic AgentsHumansCell Line, TumorCell MovementCell ProliferationCell SurvivalApoptosis

Stichwörter der Autor:innen

Osteosarcomaanti-migrationanti-proliferationfilament actin formationnortriptyline hydrochloride

Substanzen

NortriptylineDoxorubicinAntineoplastic Agents

Autor:innen und Institutionen

  • School of Pharmacy, Hyogo Medical University, Kobe, Japan.
  • School of Pharmacy, Hyogo Medical University, Kobe, Japan shimizu-t@hyo-med.ac.jp.

Zitieren

APA

Uemichi, Y., Mabuchi, M., Nagano, S., Nakao, S., & Shimizu, T. (2026). Anticancer Effects of Nortriptyline Hydrochloride in Osteosarcoma Cells Including Doxorubicin-resistant Cells. Anticancer Research, 46(7), 3687-3698. https://doi.org/10.21873/anticanres.18233

Vancouver

Uemichi Y, Mabuchi M, Nagano S, Nakao S, Shimizu T. Anticancer Effects of Nortriptyline Hydrochloride in Osteosarcoma Cells Including Doxorubicin-resistant Cells. Anticancer Research. 2026;46(7):3687-3698. doi:10.21873/anticanres.18233

BibTeX
@article{Uemichi2026,
  author = {Uemichi, Yuki and Mabuchi, Miyuki and Nagano, Shuji and Nakao, Shuhei and Shimizu, Tadashi},
  title = {Anticancer Effects of Nortriptyline Hydrochloride in Osteosarcoma Cells Including Doxorubicin-resistant Cells},
  journal = {Anticancer Research},
  year = {2026},
  volume = {46},
  number = {7},
  pages = {3687--3698},
  doi = {10.21873/anticanres.18233}
}
Kostenlos starten →